Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 11, 2019

Primary Completion Date

March 28, 2022

Study Completion Date

March 28, 2022

Conditions
Cytomegalovirus Infections
Interventions
DRUG

Letermovir

"Patients will receive intravenous or oral letermovir at a dose of 480mg/day.~Patients weighing 40 or more kilograms will receive a second, loading, dose 12 hours after the first dose of letermovir treatment.~For patients receiving concomitant cyclosporine treatment, the letermovir dose will be 240mg/day."

Trial Locations (4)

02115

Brigham and Women's Hospital, Boston

02214

Massachusetts General Hospital Cancer Center, Boston

02215

Boston Children's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Amy C. Sherman, MD

OTHER

NCT03728426 - Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | Biotech Hunter | Biotech Hunter